Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Science 24 April 1987:
Vol. 236. no. 4800, pp. 453 - 456
DOI: 10.1126/science.3551073
Prev | Table of Contents | Next

Articles

Science, Vol 236, Issue 4800, 453-456
Copyright © 1987 by American Association for the Advancement of Science

articles

Efficacy of murine malaria sporozoite vaccines: implications for human vaccine development

JE Egan, JL Weber, WR Ballou, MR Hollingdale, WR Majarian, DM Gordon, WL Maloy, SL Hoffman, RA Wirtz, I Schneider, and al. et

As part of a study of potential vaccines against malaria, the protective efficacy of sporozoite subunit vaccines was determined by using the Plasmodium berghei murine malaria model. Mice were immunized with recombinant DNA-produced or synthetic peptide-carrier subunit vaccines derived from the repetitive epitopes of the Plasmodium berghei circumsporozoite gene, or with radiation-attenuated sporozoites. Immunization with subunit vaccines elicited humoral responses that were equivalent to or greater than those elicited by irradiated sporozoites, yet the protection against sporozoite challenge induced by either of the subunit vaccines was far less than that achieved by immunization with attenuated sporozoites. Passive and adoptive transfer studies demonstrated that subunit vaccines elicited predominantly antibody-mediated protection that was easily overcome whereas irradiated sporozoites induced potent cell-mediated immunity that protected against high challenge doses of sporozoites. These studies indicate that new strategies designed to induce cellular immunity will be required for efficacious sporozoite vaccines.


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Evidence for Multiple B- and T-Cell Epitopes in Plasmodium falciparum Liver-Stage Antigen 3.
A. Toure-Balde, B.-L. Perlaza, J.-P. Sauzet, M. Ndiaye, G. Aribot, A. Tall, C. Sokhna, C. Rogier, G. Corradin, C. Roussilhon, et al. (2009)
Infect. Immun. 77, 1189-1196
   Abstract »    Full Text »    PDF »
Two Decades of Commitment to Malaria Vaccine Development: GlaxoSmithKline Biologicals.
W. R. Ballou and C. P. Cahill (2007)
Am J Trop Med Hyg 77, 289-295
   Abstract »    Full Text »    PDF »
Assessment of Antibody Protection against Malaria Sporozoites Must Be Done by Mosquito Injection of Sporozoites.
J. Vanderberg, A.-K. Mueller, K. Heiss, K. Goetz, K. Matuschewski, M. Deckert, and D. Schluter (2007)
Am. J. Pathol. 171, 1405-1406
   Full Text »    PDF »
Genetically Attenuated Plasmodium berghei Liver Stages Persist and Elicit Sterile Protection Primarily via CD8 T Cells.
A.-K. Mueller, M. Deckert, K. Heiss, K. Goetz, K. Matuschewski, and D. Schluter (2007)
Am. J. Pathol. 171, 107-115
   Abstract »    Full Text »    PDF »
C3d binding to the circumsporozoite protein carboxy-terminus deviates immunity against malaria.
E. S. Bergmann-Leitner, S. Scheiblhofer, R. Weiss, E. H. Duncan, W. W. Leitner, D. Chen, E. Angov, F. Khan, J. L. Williams, D. B. Winter, et al. (2005)
Int. Immunol. 17, 245-255
   Abstract »    Full Text »    PDF »
Unique T Cell Effector Functions Elicited by Plasmodium falciparum Epitopes in Malaria-Exposed Africans Tested by Three T Cell Assays.
K. L. Flanagan, E. A. M. Lee, M. B. Gravenor, W. H. H. Reece, B. C. Urban, T. Doherty, K. A. Bojang, M. Pinder, A. V. S. Hill, and M. Plebanski (2001)
J. Immunol. 167, 4729-4737
   Abstract »    Full Text »    PDF »
CD4+ T-Cell- and Gamma Interferon-Dependent Protection against Murine Malaria by Immunization with Linear Synthetic Peptides from a Plasmodium yoelii 17-Kilodalton Hepatocyte Erythrocyte Protein.
Y. Charoenvit, V. F. Majam, G. Corradin, J. B. Sacci Jr., R. Wang, D. L. Doolan, T. R. Jones, E. Abot, M. E. Patarroyo, F. Guzman, et al. (1999)
Infect. Immun. 67, 5604-5614
   Abstract »    Full Text »    PDF »
Infectivity of Plasmodium berghei Sporozoites Delivered by Intravenous Inoculation versus Mosquito Bite: Implications for Sporozoite Vaccine Trials.
J. A. Vaughan, L. F. Scheller, R. A. Wirtz, and A. F. Azad (1999)
Infect. Immun. 67, 4285-4289
   Abstract »    Full Text »    PDF »
Protection against malaria by vaccination with sporozoite surface protein 2 plus CS protein.
S Khusmith, Y Charoenvit, S Kumar, M Sedegah, R. Beaudoin, and S. Hoffman (1991)
Science 252, 715-718
   Abstract »    PDF »
Inability of malaria vaccine to induce antibodies to a protective epitope within its sequence.
Y Charoenvit, W. Collins, T. Jones, P Millet, L Yuan, G. Campbell, R. Beaudoin, Broderson JR, and S. Hoffman (1991)
Science 251, 668-671
   Abstract »    PDF »
Sporozoite vaccine induces genetically restricted T cell elimination of malaria from hepatocytes.
S. Hoffman, D Isenbarger, G. Long, M Sedegah, A Szarfman, L Waters, M. Hollingdale, P. van der Meide, D. Finbloom, and W. Ballou (1989)
Science 244, 1078-1081
   Abstract »    PDF »
Oral Salmonella typhimurium vaccine expressing circumsporozoite protein protects against malaria.
J. Sadoff, W. Ballou, L. Baron, W. Majarian, R. Brey, W. Hockmeyer, J. Young, S. Cryz, J Ou, G. Lowell, et al. (1988)
Science 240, 336-338
   Abstract »    PDF »
Naturally acquired antibodies to sporozoites do not prevent malaria: vaccine development implications.
S. Hoffman, C. Oster, C. Plowe, G. Woollett, J. Beier, J. Chulay, R. Wirtz, M. Hollingdale, and M Mugambi (1987)
Science 237, 639-642
   Abstract »    PDF »


To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)